Stock Events

Stock Events

Anavex Life Sciences 

$3.18
107
-$0.05-1.4% 14:41 Today

Statistics

Day High
3.22
Day Low
3.15
52W High
10.56
52W Low
2.34
Volume
117,581
Avg. Volume
1,214,819
Mkt Cap
294.23M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.17
-0.13
-0.1
-0.06
Expected EPS
-0.08
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-46.38MNet Income

Analyst Ratings

24.00Average Price Target
The highest estimate is 24.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AVXL. It's not an investment recommendation.
NVIDIA
20
NVDA
Apple
18
AAPL
Tesla
17
TSLA
Amazon
17
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap31B
Biogen focuses on neurodegenerative diseases, directly competing with Anavex's Alzheimer's and Parkinson's treatments.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly has a strong pipeline in Alzheimer's disease treatments, making it a direct competitor to Anavex.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.87B
Acadia Pharmaceuticals targets central nervous system disorders including Parkinson's disease, competing with Anavex.
Peloton Interactive
PTON
Mkt Cap2.47B
Prothena Corporation is involved in neuroscience and targets diseases like Alzheimer's, directly competing with Anavex.
Axsome Therapeutics
AXSM
Mkt Cap11.19B
Axsome Therapeutics works on central nervous system disorders, including Alzheimer's and Parkinson's, making it a competitor.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for neurodegenerative diseases, competing in the same space as Anavex.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals develops RNA-based therapeutics for diseases including neurological disorders, competing with Anavex.
Voyager Therapeutics
VYGR
Mkt Cap201.49M
Voyager Therapeutics focuses on severe neurological diseases with gene therapy, competing in Anavex's market.

About

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Show more...
CEO
Terrie Kellmeyer
Employees
34
Country
United States
ISIN
US0327973006
WKN
000A1411S

Listings

STU
DE
12X1.STU
MU
DE
12X1.MU
LSE
GB
0HFR.LSE
XNAS
US
AVXL

0 Comments

Share your thoughts

FAQ

What is Anavex Life Sciences stock price today?▼
The current price of AVXL is $3.18 USD — it has decreased by -1.4% in the past 24 hours. Watch Anavex Life Sciences stock price performance more closely on the chart.
What is Anavex Life Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Anavex Life Sciences stocks are traded under the ticker AVXL.
Is Anavex Life Sciences stock price growing?▼
AVXL stock has fallen by -6.34% compared to the previous week, the month change is a +32.85% rise, over the last year Anavex Life Sciences has showed a -68.07% decrease.
What is Anavex Life Sciences market cap?▼
Today Anavex Life Sciences has the market capitalization of 294.23M
When is the next Anavex Life Sciences earnings date?▼
Anavex Life Sciences is going to release the next earnings report on November 30, 2026.
What is Anavex Life Sciences revenue for the last year?▼
Anavex Life Sciences revenue for the last year amounts to 0 USD.
What is Anavex Life Sciences net income for the last year?▼
AVXL net income for the last year is -46.38M USD.
How many employees does Anavex Life Sciences have?▼
As of August 17, 2026, the company has 34 employees.
In which sector is Anavex Life Sciences located?▼
Anavex Life Sciences operates in the Health & Wellness sector.
When did Anavex Life Sciences complete a stock split?▼
The last stock split for Anavex Life Sciences was on October 07, 2015 with a ratio of 1:4.
Where is Anavex Life Sciences headquartered?▼
Anavex Life Sciences is headquartered in NEW YORK, United States.